HIV Clinical Trial
Official title:
Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM
Verified date | June 2017 |
Source | Friends Research Institute, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Participants receive culturally relevant and specifically tailored text messages based on the behavioral change theoretical constructs of Social Support Theory, Health Belief Model, and Social Cognitive Theory. Participants are randomized into one of three conditions for an 8-week intervention period: Group 1: culturally relevant theory-based text messages interactively transmitted by peer health educators (TXT-PHE); or, Group 2: the same culturally relevant theory-based text messages transmitted by automation (TXT-Auto); or, Group 3: assessment-only (AO) control with no theoretically based text messages.
Status | Completed |
Enrollment | 286 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Self-identified MSM - Between the ages of 18 and 65 years - Methamphetamine use within the previous 3 months - Unprotected anal intercourse (insertive or receptive) with a non-primary male partner in the previous 6 months - Not currently in treatment or seeking methamphetamine abuse treatment - Able and willing to fully charge a cellular phone daily - Able and willing to provide informed consent - Able and willing to comply with study requirements Exclusion Criteria: - Does not identify as a MSM - Not between the ages of 18 and 65 years - Has not used methamphetamine in the previous 3 months - Has not had unprotected anal intercourse (insertive or receptive) with a non-primary male partner in the previous 6 months - Currently in treatment or seeking methamphetamine abuse treatment - Unable or unwilling to fully charge a cellular phone daily - Unable or unwilling to provide informed consent - Unable or unwilling to comply with study requirements - Unable to understand the Informed Consent Form - Determined to have a more serious psychiatric condition (SCID verified) that is beyond the safe enrollment of study procedures |
Country | Name | City | State |
---|---|---|---|
United States | Friends Community Center, a division of Friends Research Institute, Inc., Los Angeles, CA 90028 | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Friends Research Institute, Inc. | University of California, Los Angeles |
United States,
Reback CJ, Grant DL, Fletcher JB, Branson CM, Shoptaw S, Bowers JR, Charania M, Mansergh G. Text messaging reduces HIV risk behaviors among methamphetamine-using men who have sex with men. AIDS Behav. 2012 Oct;16(7):1993-2002. Erratum in: AIDS Behav. 2012 Oct;16(7):2003. — View Citation
Reback CJ, Ling D, Shoptaw S, Rohde J. Developing a Text Messaging Risk Reduction Intervention for Methamphetamine-Using MSM: Research Note. Open AIDS J. 2010 May 14;4:116-22. doi: 10.2174/1874613601004030116. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Methamphetamine Use | Self-reported and/or biomarker-confirmed methamphetamine use assessed at baseline and 9-month follow-up assessment. | 9-months post randomization | |
Primary | HIV Sexual Risk Behavior | Engagement in condomless anal intercourse was assessed at baseline and 9-month post-randomization follow-up. | 9-months post randomization | |
Primary | Cost Effectiveness | Cost-effectiveness data is collected quarterly throughout the course of the study using the UNAIDS template. | up to 36 months | |
Secondary | HIV Primary Care | HIV-positive participants will be assessed according to their linkage/retention in HIV primary care and adherence to ART medication at 8-weeks, 3-, 6-, and 9-months post-randomization. | 8-weeks post randomization, 3-/6-/9-months post randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |